RU2004129739A - Рекомбинантные споры - Google Patents

Рекомбинантные споры Download PDF

Info

Publication number
RU2004129739A
RU2004129739A RU2004129739/13A RU2004129739A RU2004129739A RU 2004129739 A RU2004129739 A RU 2004129739A RU 2004129739/13 A RU2004129739/13 A RU 2004129739/13A RU 2004129739 A RU2004129739 A RU 2004129739A RU 2004129739 A RU2004129739 A RU 2004129739A
Authority
RU
Russia
Prior art keywords
dispute
protein
spore
therapeutically active
active compound
Prior art date
Application number
RU2004129739/13A
Other languages
English (en)
Russian (ru)
Inventor
Саймон Майкл КАТТИНГ (GB)
Саймон Майкл КАТТИНГ
Original Assignee
Роял Холлоуэй Энд Бедфорд Нью Колледж (Gb)
Роял Холлоуэй Энд Бедфорд Нью Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Роял Холлоуэй Энд Бедфорд Нью Колледж (Gb), Роял Холлоуэй Энд Бедфорд Нью Колледж filed Critical Роял Холлоуэй Энд Бедфорд Нью Колледж (Gb)
Publication of RU2004129739A publication Critical patent/RU2004129739A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N3/00—Spore forming or isolating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2004129739/13A 2002-03-07 2003-03-07 Рекомбинантные споры RU2004129739A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0205376.7 2002-03-07
GBGB0205376.7A GB0205376D0 (en) 2002-03-07 2002-03-07 Spore germination

Publications (1)

Publication Number Publication Date
RU2004129739A true RU2004129739A (ru) 2005-09-20

Family

ID=9932499

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004129739/13A RU2004129739A (ru) 2002-03-07 2003-03-07 Рекомбинантные споры

Country Status (9)

Country Link
US (1) US20050287168A1 (cg-RX-API-DMAC7.html)
EP (1) EP1495110A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005519123A (cg-RX-API-DMAC7.html)
KR (1) KR20040099293A (cg-RX-API-DMAC7.html)
CN (1) CN1639322A (cg-RX-API-DMAC7.html)
AU (1) AU2003214391A1 (cg-RX-API-DMAC7.html)
GB (1) GB0205376D0 (cg-RX-API-DMAC7.html)
RU (1) RU2004129739A (cg-RX-API-DMAC7.html)
WO (1) WO2003074681A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503509D0 (en) * 2005-02-19 2005-03-30 New Royal Holloway & Bedford An improved delivery agent
JP2008231063A (ja) * 2007-03-22 2008-10-02 Takano Foods Kk 納豆菌ワクチン
WO2010006326A2 (en) * 2008-07-11 2010-01-14 Tufts University Methods and compositions for spore-based vaccines
US9610333B2 (en) * 2008-07-11 2017-04-04 Tufts University Methods, compositions and kits for vegetative cell-based vaccines and spore-based vaccines
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
US20240254434A1 (en) 2019-12-18 2024-08-01 Exomnis Biotech Bv Genetically modified clostridium strains and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69002817T2 (de) * 1989-11-28 1993-12-09 Wellcome Found Vakzine.
US6280721B1 (en) * 1989-12-18 2001-08-28 Valent Biosciences, Inc. Production of Bacillus thuringiensis integrants
SK55593A3 (en) * 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
GB9401787D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB9400650D0 (en) * 1994-01-14 1994-03-09 Smithkline Beecham Biolog Expression of surface lazer proteins
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US5533973A (en) * 1995-01-13 1996-07-09 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US5531734A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Method of altering composition of nutritional product during enteral tube feeding
US5800821A (en) * 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US6372225B1 (en) * 1996-03-23 2002-04-16 The Research Foundation Of Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
US5707127A (en) * 1996-06-26 1998-01-13 Kain; Meira Three-dimensional image viewing apparatus
DE29724815U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US6730499B1 (en) * 1998-07-03 2004-05-04 Research Corporation Technologies, Inc. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6090417A (en) * 1999-03-24 2000-07-18 Kraft Foods, Inc. Nutritional fortification of natural cheese and method of making
US7186560B2 (en) * 1999-09-21 2007-03-06 Rutgers, The State University Of New Jersey High level expression of immunogenic proteins in the plastids of higher plants
GB0009470D0 (en) * 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
WO2001094599A1 (en) * 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
US6881558B1 (en) * 2000-06-26 2005-04-19 The Trustees Of The University Of Pennsylvania Expression system for cloning toxic genes
US20020150594A1 (en) * 2000-06-26 2002-10-17 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002000232A2 (en) * 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
KR20020045400A (ko) * 2000-12-08 2002-06-19 반재구 포자 표면발현 방법
GB0130789D0 (en) * 2001-12-21 2002-02-06 King S College London Application of spores

Also Published As

Publication number Publication date
US20050287168A1 (en) 2005-12-29
GB0205376D0 (en) 2002-04-24
CN1639322A (zh) 2005-07-13
WO2003074681A1 (en) 2003-09-12
AU2003214391A1 (en) 2003-09-16
KR20040099293A (ko) 2004-11-26
EP1495110A1 (en) 2005-01-12
JP2005519123A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
KR102140910B1 (ko) Chp(사이클로-히스프로)를 포함하는 섬유증의 예방, 개선 또는 치료용 조성물
EP2125076B1 (en) Spray administration of compositions including active agents such as peptides to the gastrointestinal tract
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
EP2400021A2 (en) ErbB3 based methods and compositions for treating neoplasms
CN101573376A (zh) 选择性胰高血糖素样肽-2(glp-2)类似物
JP2004501101A5 (cg-RX-API-DMAC7.html)
Moschos et al. Adjuvant synergy: the effects of nasal coadministration of adjuvants
EP3117831A1 (en) Peptides for use in promoting transport of glucose into skeletal muscle
CN102462837A (zh) 抗炎组合物
CN101584860A (zh) 重组人Claudin18.2肿瘤疫苗及其制备方法
EA008104B1 (ru) Лекарственное средство и способ лечения эректильных дисфункций
WO2017155234A1 (ko) 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
WO2003020765A3 (en) Vaccine therapies and prophylactic treatments of atherosclerotic diseases
AU2023233094A1 (en) Anti-inflammatory agents
Kakutani et al. Mucosal vaccination using claudin-4-targeting
WO2017155233A1 (ko) 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR20190134578A (ko) HBD2(human beta-defensin 2) 또는 상기 유전자와 융합된 메르스 코로나 바이러스의 에피토프 단백질을 포함하는 메르스 코로나바이러스의 예방 또는 치료용 조성물
Kajikawa et al. Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1β
CN110538316B (zh) 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物
He et al. An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholera toxin-like chimeric protein
Husband et al. Regulation of mucosal IgA responses in vivo: cytokines and adjuvants
HU230372B1 (hu) Szintetikus humán peptidek és alkalmazásuk, valamint az ezeket tartalmazó, szisztémás lupus erythematosus kezelésére alkalmas gyógyszerkészítmények
RU2004129738A (ru) Бактериальные споры
KR20190070629A (ko) HBD2(human beta-defensin 2) 또는 상기 유전자와 융합된 메르스 코르나 바이러스의 에피토프 단백질을 포함하는 메르스 코로나바이러스의 예방 또는 치료용 조성물
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070711